Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 2026

Contributed by: Business Wire

Logo

Tags

Health

Genetics

Other Science

Research

Science

Pharmaceutical

Biotechnology

Promega Corporation

More Like This

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

Merck and Promega will co-develop novel technologies that advance drug discovery.

Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies

New developments at Evosep to make clinical proteomics 100x more robust and 10x faster

Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024

GlobeNewswire associated0

Carterra Ships Its First Ultra Biosensor Platform and Finishes 2024 with Double-digit Growth and Record Revenues